fig1
![The past, present, and future of targeted therapeutic approaches in patients with diffuse pleural mesotheliomas](https://image.oaes.cc/e952bb1a-f8f5-420b-b14d-d5990d2d6a2a/5772.fig.1.jpg)
Figure 1. Graphical abstract illustrating the targets of interest described. mAB: Monoclonal antibody; TKI: tyrosine kinase inhibitor; msln: mesothelin; ADC: antibody-drug conjugate.
Figure 1. Graphical abstract illustrating the targets of interest described. mAB: Monoclonal antibody; TKI: tyrosine kinase inhibitor; msln: mesothelin; ADC: antibody-drug conjugate.
All published articles are preserved here permanently:
https://www.portico.org/publishers/oae/